P1240: Anti-Pd-1-Antibody (Tislelizumab) Combined With Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal

Zhang, L.; Liu, X.; Wang, X.; Chang, Yao-Jen; Fu, Xiaorui; Li, X.; Li, L.; Zhang, X.; Yan, Jiaqin; Nan, Feifei; Zhu, Li; Sun, Zhenqiang; Yu, Hui; Guo, Shuli; Sang, W.; Wang, L.; Zhang, M.

doi:10.1097/01.hs9.0000847824.69595.f0

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One year later, the same group reported the efficacy of another PD-1 inhibitor, nivolumab, in low doses ( 157 ). Tislelizumab in combination with chemotherapy has also proven feasible, and clinical trials with this immune checkpoint inhibitor are ongoing for both early- and advanced-stage diseases in combination with RT or chemotherapy ( 158 , 159 ). Therefore, blockade of the PD-1/PD-L1 immune axis has been shown to be a safe and effective option in the management of R/R ENKTCL.…”

Section: Treatmentmentioning

confidence: 99%

Extranodal NK-/T-cell lymphoma, nasal type: what advances have been made in the last decade?

et al. 2023

View full text Add to dashboard Cite

Extranodal NK-/T-cell lymphoma (ENKTCL) is a rare and highly aggressive malignancy with significant racial and geographic variations worldwide. In addition to the formerly “nasal-type” initial description, these lymphomas are predominantly extranodal in origin and typically cause vascular damage and tissue destruction, and although not fully understood, Epstein–Barr virus (EBV) has an important role in its pathogenesis. Initial assessment must include a hematopathology review of representative and viable tumor areas without necrosis for adequate immunohistochemistry studies, including EBV-encoded small RNA (EBER) in situ hybridization (ISH). Positron emission tomography with 18-fluorodeoxyglucose (18F-FDG-PET/CT) for accurate staging is essential, and most patients will have localized disease (IE/IIE) at diagnosis. Apart from other T-cell malignancies, the best treatment even for localized cases is combined modality therapy (chemotherapy plus radiotherapy) with non-anthracycline-based regimens. For advanced-stage disease, l-asparaginase-containing regimens have shown improved survival, but relapsed and refractory cases have very poor outcomes. Nowadays, even with a better understanding of pathogenic pathways, up-front therapy is completely based on chemotherapy and radiotherapy, and treatment-related mortality is not low. Future strategies targeting signaling pathways and immunotherapy are evolving, but we need to better identify those patients with dismal outcomes in a pre-emptive way. Given the rarity of the disease, international collaborations are urgently needed, and clinical trials are the way to change the future.

show abstract

Section: Treatmentmentioning

confidence: 99%

Extranodal NK-/T-cell lymphoma, nasal type: what advances have been made in the last decade?

et al. 2023

View full text Add to dashboard Cite

show abstract

Novel target and treatment agents for natural killer/T-cell lymphoma

et al. 2023

View full text Add to dashboard Cite

The rapidly increasing use of high-throughput screening had produced a plethora of expanding knowledge on the molecular basis of natural killer/T-cell lymphoma (NKTCL), which in turn has revolutionized the treatment. Specifically, the use of asparaginase-containing regimens has led to substantial improvement in survival outcomes in NKTCL patients. Novel treatment strategies that are currently under development include cell-surface-targeted antibodies, immune checkpoint inhibitors, Epstein-Barr virus targeted cytotoxic T lymphocyte, immunomodulatory agents, chimeric antigen receptor T cells, signaling pathway inhibitors and epigenetic targeted agents. In almost all cases, initial clinical studies of newly developed treatment are conducted in patients relapsed, and refractory NKTCL due to very limited treatment options. This review summarizes the results of these novel treatments for NKTCL and discusses their potential for likely use in NKTCL in a wider setting in the future.

show abstract